III.L 0MSFT 0.31GO.U.TO 0.3CIU.PR.A.TO 0DAL -0.02CDZ.TO 0.42NET -0.42KLAC 1.81
Amgen Inc. (AMGN)

NASDAQ:AMGN

Amgen Inc. (AMGN)

373.76
-0.39 (0.10%)
as of Jul 2, 2026, 10:54:55 pm Market Open.
106 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 5, 2026, 12:00 am

This summary was created by AI, based on 17 opinions in the last 12 months.

Amgen Inc. (AMGN) is highly regarded among experts for its stable management and well-executed innovative pipeline, featuring 15 products that have demonstrated double-digit revenue growth. Multiple analysts highlight the company's promising GLP-1 weight-loss drug currently in phase 3 testing, pointing to its potential as a game-changer in the market. Despite some concerns about slower growth compared to peers, many see AMGN as a safer investment within the biotech sector, especially given its reasonable forward P/E ratio below 20x and attractive dividend yield, which is around 3.23% to 3.46%. The stock appears to be breaking out to new highs and has recently been upgraded, reinforcing the belief in its upward trajectory as the industry evolves. Overall, AMGN is considered a solid holding for investors looking for exposure to large-cap biotech, particularly with strong earnings potential and an optimistic outlook steering toward 2027.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
GILD
PAST TOP PICK

Amgen Inc.(AMGN)

Apr 01, 2010
(A Top Pick April 21/09. Up 29.83%.) Sold his holdings at a good gain.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$60.80

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Amgen Inc.(AMGN)

Oct 14, 2009
Largest biotech stock in the US. He prefers biotech to pharma. This one is quite a reasonable company but thinks the markets are a little overdone at these levels. You won't go too far wrong but try to get it in the mid-to low $50's.
Photo of Karl BergerKarl Berger
No
Unlock Rating
$60.57

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Jul 08, 2009
Bio Pharma. Just came out with some promising test results on a bone cancer drug. Trading at about 15X earnings, which is very reasonable. Decent dividend.
Photo of Gordon ReidGordon ReidUnlock Rating
$59.50

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Amgen Inc.(AMGN)

Jun 11, 2009
Very interested in the biotech space. This one has been sitting unnoticed for a little while. Even more interesting would be the Biotech HLDRs (BBH-N). (See comments under BBH-N).
Photo of Mike S. Newton, CIM FCSIMike S. Newton, CIM FCSIUnlock Rating
$49.88

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Apr 21, 2009
Model $59.79. Drugs have been showing up. Get it before the numbers come in. Market selling off in light of expected earnings.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$46.09

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Amgen Inc.(AMGN)

Jun 22, 2007
Stocks that under perform in a bull market tend to under perform more in a bear market. They have a decelerating growth rate. Expect there will be sales reduction over the next year.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$55.96

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Amgen Inc.(AMGN)

Apr 16, 2007
From a technical perspective, he would look for it to carve out a double bottom, or a higher low.
Photo of John ManleyJohn Manley
No
Unlock Rating
$59.65

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Amgen Inc.(AMGN)

Mar 15, 2007
Can't get enthused about the pharmaceutical markets. The amount of government action, the pressures, the lawsuits, etc. makes it a high-risk area.
Photo of David CockfieldDavid Cockfield
No
Unlock Rating
$60.01

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
SELL

Amgen Inc.(AMGN)

Jun 27, 2006
There are concerns that the growth level in the business indicates there has been a dissatisfaction and lack of interest in pharmaceutical and drug companies. Below the 200 day moving average.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$63.98

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Feb 01, 2006
One of the great pharmaceutical stories. Fabulous company. The whole industry has been lackluster for last 2/3 years. This has been driven by patent litigation and lawsuits. Probably a reasonable price right now.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$76.19

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Oct 26, 2005
The biotech sector has done well this year. This stock has held up well during the market correction. Looks like it has started into a longer climb higher. Because of the current market risk, you have to pick your entries.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$75.20

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
SELL

Amgen Inc.(AMGN)

Aug 04, 2005
Model price has been the same at $53.30. The increase in the stock price has been a little overdone.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$82.68

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Mar 17, 2005
Likes the stock. The sector has been weak over the last few months. Has a pretty full pipeline of stuff that could surprise us. Trades at a reasonable multple.
Photo of Ray SteeleRay Steele
Owned
Unlock Rating
$58.95

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Amgen Inc.(AMGN)

Mar 11, 2005
Majority of money is from 3 products. Want's more diversificaion. Good balance sheet though.
Photo of Kevin Vandermeer, B.Comm, CFAKevin Vandermeer, B.Comm, CFA
No
Unlock Rating
$59.81

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Aug 13, 2004
Likes the health-care sector. One of the top companies. Has underperformed for a long time, but they are willing to be patient.
Photo of Nicholas SargenNicholas Sargen
Owned
Unlock Rating
$54.36

Stock price when the opinion was issued

$373.76

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
Showing 121 to 135 of 165 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX 0$77.65
GOOG -0.5$355.68
CAT 1.47$965
NFLX 0$77.65
AAPL -0.2$308.43

Today's Top Picks

III.L 0$2999
MSFT 0.31$390.8
GO.U.TO 0.3$9.55
CIU.PR.A… 0$
DAL -0.02$92.73

Popular Articles

Latest Sell Signals

CAT 1.47$965
ASML 5.87$1775.1899
TRI.TO -1.74$124.88
EIF.TO 2.09$132.94
MU 0.84$976.4

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like